Dutasteride y diagnóstico de cáncer de próstata

Referencias bibliográficas

• Alisky JM, Tang Y, Habermehl GK et al. Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells. Int J Clin Exp Med. 2010; 3: 245-7.
• Andriole GL, Bostwick D, Brawley OW et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study. J Urol. 2011; 185: 126- 31.
• Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362: 1192-202.
• Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasteride. J Urol. 2006; 175: 1657-62.
• Barqawi AB, O´Donnell CI, Slomos VJ et al. The effect of shortterm dutasteride intake in early-stage prostate cancer: Analysis of 148 patients who underwent three-dimensional prostate mapping biopsy. Urology. 2010; 76: 1067-71.
• Baumann C, Behbahani TE. Guías de la EAU para el cáncer de próstata: ¿cribar o no cribar? Actas Urol Esp. 2012; 36: 1.
• Bostwick DG, Qian J, Drewnowska K et al. Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: Worldwide comparison of improvement with investigator training and centralized laboratory processing. Urology. 2010; 75: 1406-11.
• Choudhury AD, Eeles R, Freedland SL et al.The role of genetic markers in the management of prostate cancer. Eur Urol. 2012; 62: 577- 87.
• Crawford ED, Andriole GL, Marberger M et al. Reduction in the risk of prostate cancer: Future directions after the prostate cancer prevention trial. Urology. 2010; 502-10.
• Gomella LG, Liu XS, Trabulsi EJ et al. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol. 2011; 18: 5875-83.
• Gurbuz C, Canat L, Atis G et al.The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. Kaohsiung J Med Sci. 2012; 28: 649-53.
• Heidenreich A, Bellmunt J, Bolla M et al. Guía de la EAU sobre el cáncer de próstata. Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado. Actas Urol Esp. 2011; 35: 501-14.
• Kaplan SA, Lee RK, Chung DE et al. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer. J Urol. 2012; 188: 757-61.
• Kattan MW, Earnshaw SR, McDade CL et al. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE Clinical Trial. Appl Health Econ Health Policy.2011; 9: 305-15.
• Marberger M, Freedland SJ, Andriole GL et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2011; 109: 1162-9.
• Martínez Ballesteros C, Martínez Salamanca JI, Carballido Rodríguez JA. Biopsia prostática: Responsabilidad diagnóstica y cambios recientes. Arch Esp Urol. 2011; 64: 735-45.
• Morote J, Planas J, Ramirez C et al. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int. 2009; 105: 481-4.
• Morote J, Ramirez C, Gómez E et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumouraggressiveness. BJU Int. 2009; 104: 486-9.
• Mostaghel EA, Geng L, Holcomb I et al. Variability in the androgen response of prostate epithelium to 5α-reductase inhibition: Implications for prostate cancer chemoprevention. Cancer Res. 2010; 70: 1286-95.
• Muller RL, Gerber L, Moreira DM et al. Serum testosterone and dihydrotestosterone and prostate cancer in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol. 2012; 62: 757-64.
• Placer J, Morote J. Utilidad del antígeno prostático específico (PSA) para el diagnóstico y estadificación de los pacientes con cáncer de próstata. Arch Esp Urol. 2011; 64: 659-80.
• Reed AB, Parekh DJ. The utility of 5α-reductase inhibitors in the prevention and diagnosis of prostate cancer. Curr Opin Urol. 2009; 19: 238-42.
• Roehrborn CG, Andriole GL, Wilson TH et al. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of Avodart and tamsulosin trial. Eur Urol. 2011; 59: 244-9.
• Shariat SF, Scherr DS, Gupta A et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol. 2011; 64: 681-94.
• Simmons MN, Berglund RK, Jones JS. A practical guide to prostate cancer diagnosis and management. Clev Clin J Med. 2011; 78: 321-31.
• Van Leeuwen PJ, Kölble K, Huland H et al. Prostate cancer detection and dutasteride: Utility and limitations of prostate-specific antigen in men with previous negative biopsies. Eur Urol. 2011; 59: 183-90.
• Zaytoun OM, Jones JS. Prostate cancer detection after a negative prostate biopsy: Lessons learnt in the Cleveland Clinic experience. Int J Urol. 2011; 18: 557-68.